image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 49.14
-2.83 %
$ 6.09 B
Market Cap
-14.5
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GH stock under the worst case scenario is HIDDEN Compared to the current market price of 49.1 USD, Guardant Health, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GH stock under the base case scenario is HIDDEN Compared to the current market price of 49.1 USD, Guardant Health, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one GH stock under the best case scenario is HIDDEN Compared to the current market price of 49.1 USD, Guardant Health, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GH

image
$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
739 M REVENUE
31.04%
-444 M OPERATING INCOME
21.45%
-436 M NET INCOME
8.98%
-240 M OPERATING CASH FLOW
26.19%
-261 M INVESTING CASH FLOW
-31.10%
-996 K FINANCING CASH FLOW
-0.21%
203 M REVENUE
0.82%
-111 M OPERATING INCOME
11.85%
-95.2 M NET INCOME
14.28%
-62.7 M OPERATING CASH FLOW
2.83%
303 M INVESTING CASH FLOW
2776.20%
-66.8 M FINANCING CASH FLOW
-2177.68%
Balance Sheet Guardant Health, Inc.
image
Current Assets 1.06 B
Cash & Short-Term Investments 840 M
Receivables 110 M
Other Current Assets 105 M
Non-Current Assets 430 M
Long-Term Investments 0
PP&E 279 M
Other Non-Current Assets 151 M
56.54 %7.42 %7.06 %18.79 %10.19 %Total Assets$1.5b
Current Liabilities 226 M
Accounts Payable 38.6 M
Short-Term Debt 0
Other Current Liabilities 187 M
Non-Current Liabilities 1.4 B
Long-Term Debt 1.14 B
Other Non-Current Liabilities 257 M
11.51 %70.30 %15.82 %Total Liabilities$1.6b
EFFICIENCY
Earnings Waterfall Guardant Health, Inc.
image
Revenue 739 M
Cost Of Revenue 290 M
Gross Profit 449 M
Operating Expenses 893 M
Operating Income -444 M
Other Expenses -7.22 M
Net Income -436 M
800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)(600m)(600m)739m(290m)449m(893m)(444m)7m(436m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
60.79% GROSS MARGIN
60.79%
-60.02% OPERATING MARGIN
-60.02%
-59.05% NET MARGIN
-59.05%
312.48% ROE
312.48%
-29.37% ROA
-29.37%
-35.31% ROIC
-35.31%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Guardant Health, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -436 M
Depreciation & Amortization 42.4 M
Capital Expenditures -35.1 M
Stock-Based Compensation 140 M
Change in Working Capital 0
Others 13.7 M
Free Cash Flow -275 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Guardant Health, Inc.
image
Wall Street analysts predict an average 1-year price target for GH of $42.5 , with forecasts ranging from a low of $36 to a high of $52 .
GH Lowest Price Target Wall Street Target
36 USD -26.74%
GH Average Price Target Wall Street Target
42.5 USD -13.51%
GH Highest Price Target Wall Street Target
52 USD 5.82%
Price
Max Price Target
Min Price Target
Average Price Target
55555050454540403535303025252020Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Guardant Health, Inc.
image
Sold
0-3 MONTHS
12.9 M USD 6
3-6 MONTHS
170 K USD 3
6-9 MONTHS
625 K USD 4
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company's 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world's most urgent challenges. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. businesswire.com - 2 weeks ago
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company's minimal residual disease (MRD) blood test, in predicting recurrence in patients with early-stage breast cancer. Guardant Reveal uses epigenomic (methylation) analysis to detect circula. businesswire.com - 2 weeks ago
Why Guardant Health Stock Surged Nearly 9% Higher Today Precision oncology specialist Guardant Health (GH 8.53%) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped almost 9% higher today. fool.com - 3 weeks ago
Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday? Guardant Health, Inc. GH stock is trading higher on Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the company's Shield multi-cancer detection (MCD) test. benzinga.com - 3 weeks ago
FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 4. businesswire.com - 3 weeks ago
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer (CRC) screening guidelines. The Shield test detects CRC signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA). The updated NCCN CRC Screening Guidelines reflect the addition of Shield with a recommendation fo. businesswire.com - 3 weeks ago
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date evaluating circulating tumor DNA (ctDNA) in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal™ test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant. businesswire.com - 3 weeks ago
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the Guardant 360® Liquid test that greatly expand its biomarker identification and cancer subtyping capabilities to help oncologists identify optimal treatment plans. The expanded applications are enabled through the multiomic profiling capabilities of the Guardant Infinity™ smart liquid biopsy platform and its AI learning engine, which analyzes la. businesswire.com - 1 month ago
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from more than 19 studies, including a landmark plenary session on the Phase 3 SERENA-6 trial, demonstrating the critical role of Guardant liquid biopsy tests in cancer screening, therapy selection and recurrence monitoring at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago. Fea. businesswire.com - 1 month ago
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company's portfolio of tumor molecular profiling tests. This new set of tests will help oncologists identify tumor subtypes and match cancer patients to the most effective targeted therapies. IHC testing is a special staining process that detects specific proteins within a tissue sample, known as t. businesswire.com - 1 month ago
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Guardant Hereditary Cancer test, a germline test that identifies genetic variants associated with cancer risk to help cancer care teams provide optimal patient care. Germline genetic testing is recommended by medical practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit fro. businesswire.com - 1 month ago
Guardant Health: A Promising Player in the Liquid Biopsy Market Explore the exciting world of Guardant Health (GH 0.54%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! fool.com - 1 month ago
8. Profile Summary

Guardant Health, Inc. GH

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 6.09 B
Dividend Yield 0.00%
Description Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Contact 505 Penobscot Drive, Palo Alto, CA, 94063 https://guardanthealth.com
IPO Date Oct. 4, 2018
Employees 1999
Officers Mr. Kumud Kalia Chief Information Officer Dr. AmirAli Talasaz Ph.D. Co-Chief Executive Officer & Director Mr. John G. Saia J.D. Chief Legal Officer & Corporate Secretary Ms. Terilyn Juarez Monroe Chief People Officer Mr. Andy Ament Senior Vice President of Operations Zarak Khurshid Vice President of Investor Relations Dr. Helmy Eltoukhy Ph.D. Co-Founder, Co-Chief Executive Officer & Chairman Ms. Gulshan Shaver J.D. Senior Vice President of Legal Affairs & Chief Compliance Officer Ms. Darya Chudova Chief Technology Officer Mr. Michael Bell Chief Financial Officer